Association of hepatitis B with antirheumatic drugs: a case–control study

REFERENCES

• Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis. 2006;65(8):983–9.
   Google Scholar
• Zingarelli S, Airo P, Frassi M, Bazzani C, Scarsi M, Puoti M. Prophylaxis and therapy of HBV infection in 20 patients treated with disease modifying antirheumatic drugs or with biological agents for rheumatic diseases. Reumatismo. 2008;60(1):22–7.
   PubMedGoogle Scholar
• Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheuma-toid arthritis. Arthritis Rheum. 2008;59(6):762–84.
   PubMed Web of Science ®Google Scholar
• Fauci AS, Kasper DL, Longo DL, et al. Harrison's principles of internal medicine. 17th Edition. New York: McGraw-Hill; 2008.
   Google Scholar
• Tamori A, Koike T, Goto H, et al. Prospective study of reacti-vation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol. 2011;46(4):556–64.
   PubMed Web of Science ®Google Scholar
• Mori S. Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modi-fying antirheumatic drugs. Mod Rheumatol. 2011.
   Google Scholar
• Caporali R, Bobbio-Pallavicini F, Atzeni F, et al. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res (Hoboken). 2010;62(6):749–54.
   PubMed Web of Science ®Google Scholar
• Vassilopoulos D, Apostolopoulou A, Hadziyannis E, et al. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis. 2010;69(7):1352–5.
   PubMed Web of Science ®Google Scholar
• Tsubouchi H, Kumada H, Kiyosawa K, et al. Prevention of immunosuppressive therapy or chemotherapy-induced reactiva-tion of hepatitis B virus infection Joint report of the Intractable Liver Diseases Study Group of Japan and the Japanese Study Group of the standard antiviral therapy for viral hepatitis. Kanzo. 2009;50(1):38–42.
   Google Scholar
• Oshima Y, Tojo A. Pulmonary alveolar hemorrhage possibly associated with lenalidomide use. Int J Hematol. 2011;94(3): 296–7.
   PubMed Web of Science ®Google Scholar
• Oshima Y, Tojo A. Attractive tools for systematic case accu-mulation. Int J Hematol. 2011;94(4):413–4.
   PubMed Web of Science ®Google Scholar
• Murashige N, Tanimoto T, Oshima Y. Interstitial lung disease and gefitinib. N Engl J Med. 2010;363(16):1578–9. author reply 1579–80.
   Google Scholar
• Oshima Y. Characteristics of drug-associated rhabdomyolysis: analysis of 8,610 cases reported to the US Food and Drug Administration. Intern Med. 2011;50(8):845–53.
   PubMed Web of Science ®Google Scholar
• Pariente A, Gregoire F, Fourrier-Reglat A, Haramburu F, Moore N. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Sat'. 2007;30(10):891–8.
   Google Scholar
• Umemura T, Kiyosawa K. Fatal HBV reactivation in a subject with anti-HBs and anti-HBc. Intern Med. 2006;45(12):747–8.
   PubMed Web of Science ®Google Scholar
• Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterol-ogy. 1991;100(1):182–8.
   PubMed Web of Science ®Google Scholar
• Hass M, Hannoun C, Kalinina T, Sommer G, Manegold C, Gunther S. Functional analysis of hepatitis B virus reactivating in hepatitis B surface antigen-negative individuals. Hepatology. 2005;42(1):93–103.
   PubMed Web of Science ®Google Scholar
• Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepi-demiol Drug Sat'. 2004;13(8):519–23.
   Google Scholar
• Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepa-tology. 2006;43(2):209–20.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Hsiung CA, Su U, et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology. 2003;37(6):1320–8.
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Kono D, Chung J, et al. Polyclonality and multi-specificity of the CTL response to a single viral epitope. J Immunol. 1998;161(11):5842–50.
   PubMed Web of Science ®Google Scholar
• Thimme R, Wieland S, Steiger C, et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol. 2003;77(1):68–76.
   PubMed Web of Science ®Google Scholar
• Ando K, Moriyama T, Guidotti LG, et al. Mechanisms of class I restricted immunopathology. A transgenic mouse model of ful-minant hepatitis. J Exp Med. 1993;178(5):1541–54.
   Google Scholar
• Pfizer Japan Inc. Interview form for Etemelcept. In: http://www. info.pmda.go.jp/go/interview/2/671450_3999424G1025_2_1F. 18 ed. Tokyo, Japan; 2012.
   Google Scholar
• Mitsubishi Tanabe Pharma Corporation. Interview form for Inf-liximab. In: http://www.info.pmda.go.jp/go/interview/1/400315_ 2399402F1026_1_200_1F. 20 ed. Osaka, Japan; 2012.
   Google Scholar
• Abbott Japan Co. Ltd. Interview form for Adalimumab. In: http://www.info.pmda.go.jp/go/interview/1/100159_3999426G10 24_1_005_1F. 5 ed. Tokyo, Japan; 2010.
   Google Scholar
• Strand V, Kimberly R, Isaacs JD. Biologic therapies in rheuma-tology: lessons learned, future directions. Nat Rev Drug Discov. 2007;6(1):75–92.
   PubMed Web of Science ®Google Scholar
• Ioannou GN. Hepatitis B virus in the United States: infection, exposure, and immunity rates in a nationally representative sur-vey. Ann Intern Med. 2011;154(5):319–28.
   PubMed Web of Science ®Google Scholar
• Li S, Kaur PP, Chan V, Berney S. Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infiiximab, etanercept, and ada-limumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients. Clin Rheumatol. 2009;28(7):787–91.
   PubMed Web of Science ®Google Scholar
• Benucci M, Manfredi M, Mecocci L. Effect of etanercept plus lamivudine in a patient with rheumatoid arthritis and viral hep-atitis B. J Clin Rheumatol. 2008;14(4):245–6.
   Google Scholar